Trial Profile
Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Laronidase (Primary)
- Indications Mucopolysaccharidosis I
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 03 Dec 2017 Planned End Date changed from 10 Nov 2017 to 10 Nov 2018.
- 03 Dec 2017 Planned primary completion date changed from 1 Jun 2016 to 18 Feb 2017.